Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 9, Issue 6, Pages 482-493Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3030
Keywords
-
Funding
- Iacocca Foundation
Ask authors/readers for more resources
Although drug development has advanced for autoimmune diseases, many current therapies are hampered by adverse effects and the frequent destruction or inactivation of healthy cells in addition to pathological cells. Targeted autoimmune therapies capable of eradicating the rare autoreactive immune cells that are responsible for the attack on the body's own cells are yet to be identified. This Review presents a new emerging approach aimed at selectively destroying autoreactive immune cells by specific activation of tumour necrosis factor receptor 2 (TNFR2), which is found on autoreactive and normal T lymphocytes, with the potential of avoiding or reducing the toxicity observed with existing therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available